Mohit Khera, MD, MBA, MPH

Mohit Khera, MD, MBA, MPH

Baylor College of Medicine

Houston, Texas

Mohit Khera, MD, MBA, MPH, is a Professor of Urology at Baylor College of Medicine in Houston, Texas, where he holds the F. Brantley Scott Chair in Urology. He additionally serves Baylor College as the Director of the Laboratory for Andrology Research at McNair Medical Institute and the Medical Director of the Executive Health Program. Dr. Khera specializes in male and female sexual dysfunction, men’s health, male infertility, sexual dysfunction, declining testosterone levels in aging men, and hormone replacement therapy. His research interests include studies on the efficacy of botulinum toxin type A in treating Peyronie’s disease, genetic and epigenetic studies of post-finasteride syndrome patients, and testosterone replacement therapy.

Dr. Khera earned his medical degree from the University of Texas Medical School at San Antonio. He then completed his residency in the Scott Department of Urology at Baylor College of Medicine in Houston, Texas, where he subsequently completed a one-year fellowship in Male Reproductive Medicine and Surgery under the guidance of Dr. Larry I. Lipshultz.  

Dr. Khera has authored or co-authored numerous book chapters, including those in the acclaimed Campbell-Walsh Urology textbook, Clinical Gynecology, and the fourth edition of Infertility in the Male. He also co-edited the third edition of the popular book Urology and the Primary Care Practitioner and published Recoupling: A Couple’s 4 Step Guide to Greater Intimacy and Better Sex. Dr. Khera has authored more than 90 articles in scientific journals and has lectured extensively worldwide on testosterone replacement therapy and sexual dysfunction. He is a member of the Sexual Medicine Society of North America, the American Urological Association, the American Society of Andrology, the American Medical Association, the Indian Doctors Association of Houston, the Harris County Medical Society, and the Texas Association of Genitourinary Surgeons. He serves on the Strategy and Development Committee for the International Society for Sexual Medicine and on the Board of Directors for the Society of Urologic Prosthetic Surgeons. 

Talks by Mohit Khera, MD, MBA, MPH

TRAVERSE Trial Update

TRAVERSE Trial Update

| Apr 2024

Mohit Khera, MD, MBA, MPH, presents the latest updates from the TRAVERSE Trial, examining the cardiovascular effects of testosterone therapy. This presentation is an update to Dr. Khera’s “Results from the TRAVERSE Trial” lecture, which was presented to the Grand Rounds in Urology audience in August 2023.

Dr. Khera begins by reviewing the history of the TRAVERSE Trial and its initial results regarding the impact of testosterone therapy on cardiovascular health. He outlines the design of the TRAVERSE Trial, which concluded in January 2024 with a final enrollment count of 5,246 men.

In addition to the original secondary and tertiary endpoints regarding cardiovascular safety and prostate safety, Dr. Khera discusses other secondary endpoints in the trial. These endpoints were sexual function, depression, bone fractures, diabetes, and anemia.

Dr. Khera concludes by delving into the final results of testosterone therapy on all endpoints in the trial. He notes that the results indicate that testosterone therapy does not significantly worsen BPH symptoms and may protect against the development of anemia. However, he notes that testosterone therapy may raise the risk of bone fractures and pulmonary embolisms.

Read More
Testosterone to Improve the Diagnosis and Treatment of Prostate Cancer

Testosterone to Improve the Diagnosis and Treatment of Prostate Cancer

| Nov 2023

Mohit Khera, MD, MBA, MPH, explores how testosterone can help diagnose and treat prostate cancer. He explains that low testosterone is a biomarker for prostate cancer, a predictor of who will progress on active surveillance (AS), and a risk factor for biochemical recurrence after prostatectomy. Further, testosterone therapy can be a treatment for metastatic prostate cancer. 

Dr. Khera argues that while testosterone should not be considered a monotherapy, it can augment treatment. He explains PSA has poor sensitivity and addresses biomarker tests that seek to improve sensitivity and specificity. Dr. Khera asserts the ratio of testosterone to PSA has sensitivity of 82 percent and specificity of 62 percent, with lower costs than biomarker tests. He cites data explaining for men with low testosterone, PSA alone may not be accurate. Dr. Khera cites another study on testosterone as a predictor of upstaging and upgrading in low-risk AS patients. It concludes testosterone should be a selection criterion for inclusion of low-risk prostate cancer patients in AS programs.

Dr. Khera explains lower preoperative testosterone levels increase the risk for prostate cancer recurrence. Dr. Khera turns to treatment options, looking at bipolar androgen therapy (BAT) that includes patients with advanced disease receiving high doses of testosterone which results in a 50 percent reduction in both PSA and metastatic disease. Dr. Khera cites a study on BAT for asymptomatic men with castration-resistant prostate cancer; the BAT was well-tolerated and resulted in high response rates. 

Dr. Khera cites the TRANSFORMER study comparing BAT vs. enzalutamide. Data show no difference in survival; however, patients who switched from BAT to enzalutamide had the highest survival rates. Dr. Khera concludes that testosterone can improve prostate cancer diagnosis and counseling for patients on biochemical recurrence; it comes with significantly less cost and offers greater quality of life.

Read More
Results from the TRAVERSE Trial

Results from the TRAVERSE Trial

| Aug 2023

Mohit Khera, MD, MBA, MPH, provides an update on the results of the landmark TRAVERSE Trial, which examined the potential cardiovascular effects of testosterone therapy in men. After reviewing the complex recent history and controversies surrounding testosterone therapy, Dr. Khera walks through the TRAVERSE Trial, a randomized, double-blind, placebo-controlled study of over 5,000 hypogonadal men who either had cardiovascular disease (CVD), or were at increased risk for CVD over 5 years.

Dr. Khera highlights the thoroughness of the trial’s design, giving special focus to the primary, secondary, and tertiary endpoints relating to any MACE events for the trial participants. He concludes by presenting the results of the trial; testosterone therapy, for a mean duration of 22 months, did not increase the risk of major cardiovascular events in hypogonadal men over 40 years old with previous CVD or elevated risk for CVD.

Read More